Laquinimod-d5
Product Specifications
Product Name Alternative
ABR-215062-d5
UNSPSC Description
Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research[1].
Target Antigen
Apoptosis; Isotope-Labeled Compounds; NF-κB
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis;NF-κB;Others
Field of Research
Inflammation/Immunology
Purity
98.25
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
[2H]C1=C([2H])C([2H])=C(N(C(C2=C(O)C3=C(N(C)C2=O)C=CC=C3Cl)=O)CC)C([2H])=C1[2H]
Molecular Weight
361.83
References & Citations
[1]Varrin-Doyer M, et al. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp Neurol. 2014 Dec;262 Pt A:66-71.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Clinical Information
No Development Reported
CAS Number
1214267-09-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
